Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Hematopoietic Stem Cell Transplant for Blood Cancer
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Hematopoietic Stem Cell Transplant for Blood Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (1 September 2019)

Special Issue Editors

Prof. Dr. Jonas Mattsson

E-Mail Website
Guest Editor
Department of Oncology and Pathology, Karolinska Institutet, Department of Hematology, Oslo University Hospital and Clinical Immunology, Karolinska University Hospital, Huddinge, SE-141 86 Stockholm
Interests: stem cell transplantation; immunotherapy; GVHD
Prof. Dr. Andrea Bacigalupo

E-Mail Website
Guest Editor
Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli, Universita' Cattolica deI Sacro Cuore, Rome, Italy
Interests: stem cell transplantation; immunotherapy; myeloid leukemia; myelodysplastic syndrome

Special Issue Information

Dear Colleagues,

Allogeneic hematopoietic stem cell transplantation is today a standard treatment for several hematological malignancies and non-malignant disorders. The number of allogeneic transplants is steadily increasing world-wide. This field has been driven by substantial research activity enabling both improved clinical outcome and quality of life. Conditioning therapy has been refined and today there is increased focus on a personal medicine approach with more individualized therapy. Optimizing the stem cell source and increasing donor options have also contributed to the development these last years. Lower treatment toxicity, better surveillance and improved treatments of infections have greatly decreased transplant-related mortality leading to improved overall survival. However, relapse of the underlying disease is still an area which needs improvement. There is much optimism around the new and exciting developments in immunotherapy such as CAR T cell therapy, checkpoint inhibitor and antibody-mediated therapies.

In summary, a better understanding how to further develop new tools to combat relapse and further refine the transplant procedure is necessary to offer this treatment to an increased number of patients with improved outcome and sustained quality of life.

Prof. Dr. Jonas Mattsson
Prof. Dr. Andrea Bacigalupo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • allogeneic
  • stem cell transplantation
  • GVHD
  • Relapse
  • conditioning therapy
  • immunotherapy
  • CAR T cell
  • haplo

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 2286 KiB  
Review
Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation
by Hyun Don Yun, Ankur Varma, Mohammad J. Hussain, Sunita Nathan and Claudio Brunstein
J. Clin. Med. 2019, 8(11), 1968; https://doi.org/10.3390/jcm8111968 - 14 Nov 2019
Cited by 26 | Viewed by 7575
Abstract
Umbilical cord blood transplantation (UCBT) has been an important donor source for allogeneic hematopoietic stem cell transplantation, especially for patients who lack suitable matched donors. UCBT provides unique practical advantages, such as lower risks of graft-versus-host-disease (GVHD), permissive HLA mismatch, and ease of [...] Read more.
Umbilical cord blood transplantation (UCBT) has been an important donor source for allogeneic hematopoietic stem cell transplantation, especially for patients who lack suitable matched donors. UCBT provides unique practical advantages, such as lower risks of graft-versus-host-disease (GVHD), permissive HLA mismatch, and ease of procurement. However, there are clinical challenges in UCBT, including high infection rates and treatment-related mortality in selected patient groups. These clinical advantages and challenges are tightly linked with cell-type specific immune reconstitution (IR). Here, we will review IR, focusing on T and NK cells, and the impact of IR on clinical outcomes. Better understanding of the immune biology in UCBT will allow us to further advance this field with improved clinical practice. Full article
(This article belongs to the Special Issue Hematopoietic Stem Cell Transplant for Blood Cancer)
►▼ Show Figures

Figure 1

17 pages, 1729 KiB  
Review
Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician
by Catalin Constantinescu, Constantin Bodolea, Sergiu Pasca, Patric Teodorescu, Delia Dima, Ioana Rus, Tiberiu Tat, Patriciu Achimas-Cadariu, Alina Tanase, Ciprian Tomuleasa and Hermann Einsele
J. Clin. Med. 2019, 8(6), 884; https://doi.org/10.3390/jcm8060884 - 20 Jun 2019
Cited by 15 | Viewed by 6991
Abstract
The initial management of the hematology patient in a critical state is crucial and poses a great challenge both for the hematologist and the intensive care unit (ICU) physician. After years of clinical practice, there is still a delay in the proper recognition [...] Read more.
The initial management of the hematology patient in a critical state is crucial and poses a great challenge both for the hematologist and the intensive care unit (ICU) physician. After years of clinical practice, there is still a delay in the proper recognition and treatment of critical situations, which leads to late admission to the ICU. There is a much-needed systematic ABC (Airway, Breathing, Circulation) approach for the patients being treated on the wards as well as in the high dependency units because the underlying hematological disorder, as well as disease-related complications, have an increasing frequency. Focusing on score-based decision-making on the wards (Modified Early Warning Score (MEWS), together with Quick Sofa score), active sepsis screening with inflammation markers (C-reactive protein, procalcitonin, and presepsin), and assessment of microcirculation, organ perfusion, and oxygen supply by using paraclinical parameters from the ICU setting (lactate, central venous oxygen saturation (ScVO2), and venous-to-arterial carbon dioxide difference), hematologists can manage the immediate critical patient and improve the overall outcome. Full article
(This article belongs to the Special Issue Hematopoietic Stem Cell Transplant for Blood Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop